Anavex Life Sciences Corp. AVXL
1.11 USD -0.15 (-11.90%)
At closeNov 5, 2026, 5:35 PM EST
1.14 +0.03 +3.05%
After hours · Nov 5, 5:35 PM ET
1.07 Day range 1.26
1.11 52-week range 7.40
- YTD
- -68.82%
- 1 year
- -84.82%
News
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Anavex Life Sciences Corp. of Class Action Lawsuit and Upcoming Deadlines - AVXL NEW YORK, Nov. 5, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ: AVXL). Such investors…
globenewswire.com SHAREHOLDER ALERT: Bronstein Gewirtz & Grossman, LLC Announces Class Action Against Anavex Life Sciences Corp. (NASDAQ: AVXL) — Investors Who Suffered Losses Are Encouraged to Contact the Firm Nationally Recognized Firm Urges Anavex Investors to Explore Class Action Representation Lead Plaintiff Deadline: November 30, 2026. Investors who purchased (NASDAQ: AVXL) securities between November…
newsfilecorp.com AVXL SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Anavex (AVXL) Investors of Securities Class Action Lawsuit Deadline on November 30, 2026 Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Anavex To Contact Him Directly To Discuss Their Options If you purchased or acquired…
newsfilecorp.com ANAVEX DEADLINE: ROSEN, A TOP-RANKED LAW FIRM, Encourages Anavex Life Sciences Corp. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - AVXL New York, New York--(Newsfile Corp. - November 4, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Anavex Life Sciences Corp. (NASDAQ: AVXL) between…
newsfilecorp.com AVXL EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Anavex (AVXL) Investors of Securities Class Action Lawsuit Deadline on November 30, 2026 Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Anavex To Contact Him Directly To Discuss Their Options If you purchased or acquired…
newsfilecorp.com Kaplan Fox Notifies Investors of Anavex Life Sciences Corp. (AVXL) of the Lead Plaintiff Deadline on November 30, 2026 New York, New York--(Newsfile Corp. - November 3, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Anavex Life Sciences Corp. ("Anavex" or the…
globenewswire.com Anavex Life Sciences Corp. Investors Seeking Lead Plaintiff Role Have Until November 30th to Contact Bragar Eagel & Squire, P.C. Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Anavex (AVXL) To Contact Him Directly To Discuss Their Options
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Anavex Life Sciences Corp. of Class Action Lawsuit and Upcoming Deadlines – AVXL NEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Anavex Life Sciences Corp. (“Anavex” or the “Company”) (NASDAQ: AVXL). Such…
globenewswire.com ANAVEX DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AVXL NEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Anavex Life Sciences Corp. (NASDAQ: AVXL) between November 26,…
newsfilecorp.com ANAVEX DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - AVXL New York, New York--(Newsfile Corp. - November 3, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Anavex Life Sciences Corp. (NASDAQ: AVXL) between…
globenewswire.com DEADLINE ALERT for Fluence Energy, Inc. (FLNC), Qfin Holdings, Inc. (QFIN), Endava plc (DAVA), and Anavex Life Sciences Corp. (AVXL): The Law Offices of Frank R. Cruz Reminds Investors of Lead Plaintiff Deadlines in Securities Fraud Class Actions Investors in Fluence Energy, Inc., Qfin Holdings, Inc., Endava plc, and Anavex Life Sciences Corp. have upcoming deadlines to seek lead plaintiff appointment in pending securities class actions…
newsfilecorp.com Bronstein, Gewirtz & Grossman LLC Urges Anavex Life Sciences Corp. Investors to Act: Class Action Filed Alleging Investor Harm New York, New York--(Newsfile Corp. - November 3, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed…
globenewswire.com Anavex Life Sciences Names Terrie Kellmeyer, Ph.D., as President and Chief Executive Officer and Member of the Board of Directors Seasoned biopharmaceutical executive with more than 30 years of leadership experience spanning clinical development, regulatory strategy and operational execution appointed to lead company into new…
globenewswire.com Deadline Alert: Anavex Life Sciences Corp. Investors Have Until November 30, 2026 to Seek Lead Plaintiff Role in Securities Fraud Class Action, Glancy Prongay Wolke & Rotter LLP Reminds Investors Class action covers investors who bought Anavex Life Sciences Corp. securities between November 26, 2025 and August 28, 2026; complaint alleges the company failed to disclose material adverse facts…
newsfilecorp.com ANAVEX LIFE SCIENCES DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - AVXL New York, New York--(Newsfile Corp. - November 2, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Anavex Life Sciences Corp. (NASDAQ: AVXL) between…
globenewswire.com SHAREHOLDER ALERT: Bronstein Gewirtz & Grossman, LLC Announces Class Action Against Anavex Life Sciences Corp. (NASDAQ: AVXL) — Investors Who Suffered Losses Are Encouraged to Contact the Firm Nationally Recognized Firm Urges Anavex Investors to Explore Class Action Representation Lead Plaintiff Deadline: November 30, 2026. Investors who purchased (NASDAQ: AVXL) securities between November…
newsfilecorp.com AVXL INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Anavex (AVXL) Investors of Securities Class Action Lawsuit Deadline on November 30, 2026 Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Anavex To Contact Him Directly To Discuss Their Options If you purchased or acquired…
globenewswire.com Robbins LLP Urges AVXL Shareholders to Contact the Firm for Information About the Anavex Life Sciences Corp. Class Action Lawsuit SAN DIEGO, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of persons and entities who purchased or otherwise…
newsfilecorp.com ANAVEX DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - AVXL New York, New York--(Newsfile Corp. - November 1, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Anavex Life Sciences Corp. (NASDAQ: AVXL) between…
globenewswire.com ANAVEX DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages Anavex Life Sciences Corp. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AVXL NEW YORK, Oct. 31, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Anavex Life Sciences Corp. (NASDAQ: AVXL) between November 26,…
newsfilecorp.com AVXL UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Anavex (AVXL) Investors of Securities Class Action Lawsuit Deadline on November 30, 2026 Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Anavex To Contact Him Directly To Discuss Their Options If you purchased or acquired…
prnewswire.com Anavex Deadline: AVXL Investors with Losses in Excess of $100K Have Opportunity to Lead Anavex Life Sciences Corp. Securities Fraud Lawsuit Filed by The Rosen Law Firm NEW YORK, Oct. 31, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Anavex Life Sciences Corp. (NASDAQ: AVXL) between November 26, 2025…
newsfilecorp.com ANAVEX DEADLINE: ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - AVXL New York, New York--(Newsfile Corp. - October 30, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Anavex Life Sciences Corp. (NASDAQ: AVXL) between…
newsfilecorp.com AVXL CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Anavex (AVXL) Investors of Securities Class Action Lawsuit Deadline on November 30, 2026 Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Anavex To Contact Him Directly To Discuss Their Options If you purchased or acquired…
newsfilecorp.com Kaplan Fox Urges Anavex Life Sciences Corp. (AVXL) Investors to Contact the Firm Before the Deadline on November 30, 2026 New York, New York--(Newsfile Corp. - October 30, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Anavex Life Sciences Corp. ("Anavex" or the…
newsfilecorp.com ANAVEX DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - AVXL New York, New York--(Newsfile Corp. - October 29, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Anavex Life Sciences Corp. (NASDAQ: AVXL) between…
globenewswire.com Kirby McInerney LLP Alerts Investors Who Acquired Anavex Life Sciences Corp. AVXL Securities Between November 26, 2025 and August 28, 2026 of Pending Lawsuit NEW YORK, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds Anavex Life Sciences Corp. (“Anavex” or the “Company”) (NASDAQ: AVXL) investors of the November 30, 2026 deadline to seek the…
globenewswire.com DEADLINE ALERT for Fluence Energy, Inc. (FLNC), Qfin Holdings, Inc. (QFIN), Endava plc (DAVA), and Anavex Life Sciences Corp. (AVXL): The Law Offices of Frank R. Cruz Reminds Investors of Lead Plaintiff Deadlines in Securities Fraud Class Actions Investors in Fluence Energy, Inc., Qfin Holdings, Inc., Endava plc, and Anavex Life Sciences Corp. have upcoming deadlines to seek lead plaintiff appointment in pending securities class actions…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Anavex Life Sciences Corp. of Class Action Lawsuit and Upcoming Deadlines - AVXL NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ: AVXL). Such…
benzinga.com Anavex Life Sciences Completes Clinical Conduct Of Drug-Drug Interaction, Absorption, Distribution, Metabolism And Excretion Trials Of Blarcamesine; Receives FDA Clearance For Its Investigational New Drug Application In Fragile X Syndrome; To Meet With FDA To Discuss Inclusion Of Participants In Its Phase 3 Rett Syndrome Trial Anavex Life Sciences Corp. ("Anavex" or the "Company"), a clinical-stage biopharmaceutical company developing innovative treatments for central nervous system diseases with significant unmet medical
benzinga.com Anavex Life Sciences Receives FDA Clearance to Proceed Ahead With Its Planned Clinical Trial Under Its Investigational New Drug Application For ANAVEX 2-73 For Fragile X Syndrome Anavex Life Sciences Corp. ("Anavex" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system diseases with significant…
benzinga.com Anavex Life Sciences Regains Nasdaq Compliance Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system ("CNS")
benzinga.com Anavex Life Sciences Q3 EPS $0.08 Beats $(0.08) Estimate Anavex Life Sciences (NASDAQ:AVXL) reported quarterly earnings of $0.08 per share which beat the analyst consensus estimate of $(0.08) by 200 percent. This is a 150 percent increase over losses of…
benzinga.com Anavex Life Sciences Urges Stockholders To Reject Attempt By PVG Asset Management And Patrick S. Adams To Acquire Control Of The Company Nominates Two New Independent Directors, Mr. Gautam Patel and Dr. Adrian Senderowicz, Who Bring Deep, Relevant Experience in Life SciencesMr. Patel and Dr. Senderowicz to Stand for Election at 2026…- benzinga.com Anavex Life Sciences Q2 EPS $(0.06) Beats $(0.08) Estimate Anavex Life Sciences (NASDAQ:AVXL) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.08) by 25 percent. This is a 53.85 percent increase over losses of…
benzinga.com Anavex Life Sciences Receives Expected Delinquency Notification From Nasdaq Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system (CNS)…
benzinga.com Anavex Life Sciences Announces New Findings On The Shared Biology Between Autism Spectrum Disorder And Alzheimer's Disease Multiple peer-reviewed publications point to biological link between autism spectrum disorder (ASD) and Alzheimer's disease (AD), including shared disruptions in autophagy.Epidemiological data show…- benzinga.com Anavex Life Sciences Continues Dialogue With EMA To Advance Development Program Of Oral Blarcamesine In Early Alzheimer's Disease Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's…
benzinga.com Crude Oil Moves Lower; Cintas Raises FY2026 Forecast The Dow Jones index gained over 300 points, with the S&P 500 and NASDAQ also rising. Cintas Corp posted strong earnings and raised its forecast, while Sarepta Therapeutics and Braze Inc saw…
benzinga.com Dow Surges Over 300 Points; Chewy Shares Jump On Upbeat Earnings US stocks rise with the Dow gaining over 300 points. Chewy shares jump 14%. Sarepta Therapeutics surges 29%. Oil down 2.1%, gold up 3.2%.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session 
benzinga.com Anavex Life Sciences Stock Crushed As European Alzheimer's Drug Filing Pulled After EMA Pushback Anavex shares fall after pulling EU filing for blarcamesine in Alzheimer's; EMA feedback prompts more data work.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session - benzinga.com Anavex Withdraws EU Filing For Alzheimer's Treatment After Regulator Feedback Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's…
- benzinga.com Anavex Life Sciences Presents New Data Of Blarcamesine At AD/PD 2026 Conference; Data Show Brain-Volume Preservation Correlates With Patient Outcomes Long-term clinical data indicate 77.4 weeks (17.8 months) time saved with oral blarcamesine compared to ADNI1 control group after 144 weeks (33.1 months) of treatmentOral presentation at the AD/PD™…
benzinga.com Anavex Life Lead Drug Targets Early Alzheimer's Cause - New Study Highlights New study links early brain cleanup failure to Alzheimer's, supporting Anavex Life drug approach targeting disease before plaques form.- benzinga.com Anavex Life Sciences Announces New Study Supporting Blarcamesine As A Potential Alzheimer's Treatment Anavex highlighted a new peer-reviewed study published by University of California in Proceedings of the National Academy of Sciences, Nexus1 (Shoff et al., 2026) supports the hypothesis that…
benzinga.com Anavex Tests Parkinson's Drug That May Help Regrow Brain Cells Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's…
benzinga.com What's Going On With Anavex Life Sciences Stock On Wednesday? Anavex Life Sciences' stock rises despite no news, up over 40% this year as investors watch Alzheimer's program updates and analyst targets.- benzinga.com HC Wainwright & Co. Reiterates Buy on Anavex Life Sciences, Maintains $20 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Anavex Life Sciences (NASDAQ:AVXL) with a Buy and maintains $20 price target.